Ensuring top value of a product throughout the lifecycle process involves managing issues related to evaluating a potential product; Identifying the best people for a project, recognizing key value factors of a product, and managing the size, flow and duration of a project. This panel specifically addressed:
- How does your evaluation of a project differ in the big Pharma setting vs. a more entrepreneurial setting?
- What factors do you consider in determining whether their will be life after the patent on the active
- How have considerations changed in doing research (basic and developmental) in the last 10 years?
- What are some sources for evaluating the likelihood of success of a project?
Presenters included:
- Lisa Alexander, Corporate Patent Counsel, Novartis Institutes for Biomedical Research; Novartis Vaccines & Diagnostics
- Matt Bastardi, Vice President, Business Development & Licensing, Covidien
- James Burnes, Director, Health Care Investment Banking, Credit Suisse Securities LLC
- R. Brian McCaslin, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
Related Insights
24 January 2025
Foley Viewpoints
Incoming Environmental Protection Agency (EPA) Personnel and Impact on Enforcement
To nobody’s surprise, it is already evident that President Trump’s second term will mark a significant shift in environmental regulation and policy from the Biden Administration.
24 February 2025
Events
Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking in the Health Care Compliance Board & Compliance Committee Conference in the panel “Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General.”
24 January 2025
Foley Viewpoints
Corporate Transparency Act Enforcement Remains Paused
On January 23, 2025, the U.S. Supreme Court issued a stay of the nationwide preliminary injunction issued by a federal district court in Texas in December 2024 in the Texas Top Cop Shop litigation.